Edwards Lifesciences | EW - Gewinn Vor Steuern

Aktienkurs
82.54
Täglich Wechseln
-0.43 -0.52%
Monatlich
1.24%
Jährlich
10.36%
Q2 Prognose
79.74




Gewinn Vor Steuern Veränderung Datum
Abbott USD 2.39B 27M 2026-03
Artivion USD 11.4M 7.84M 2025-12
AtriCure USD 394K 1.97M 2026-03
Baxter International USD -756M 877M 2025-12
Becton, Dickinson and Co. USD 393M 117M 2025-12
Boston Scientific USD 700M 238M 2025-12
Cooper Companies USD 116.8M 137.4M 2025-09
Dexcom USD 340.7M 40.7M 2025-12
Edwards Lifesciences USD 348.4M 51.8M 2025-09
Globus Medical USD 169.23M 25.24M 2025-12
ICU Medical USD -15.9M 86.2M 2025-12
Inogen USD -6.06M 467K 2024-09
Insulet USD 113M 27.2M 2026-03
Integra LifeSciences USD -2.41M 6.72M 2026-03
Intuitive Surgical USD 955.6M 100.4M 2025-12
J&J USD 7.82B 2.86B 2026-03
Masimo USD 71.3M 3.6M 2026-03
Medtronic USD 2.1B 224M 2025-09
Merit Medical Systems USD 51.06M 22.12M 2025-12
Stryker USD 1.7B 676M 2025-12
Tandem Diabetes Care USD 4.68M 29.82M 2025-12
Teleflex USD 218.94M 657.52M 2025-12
Zimmer Biomet Holdings USD 98M 320.7M 2025-12